Knowledge, Awareness and Attitude on HPV, HPV Vaccine and Cervical Cancer among the College Students in India

Cervical cancer is a preventable disease that is highly prevalent among American Indian (AI) women. Some types of the Human papillomavirus (HPV) has been identified as causing cervical cancer in women and other less common cancers such as cancer of the anus, vagina, vulva, and oral cavity. Two vaccines, Gardasil® and Cervarix®, are available for primary protection against HPV. Despite its proven efficacy, additional efforts are needed to improve HPV update among AI women. Our project was designed to assess HPV vaccine readiness among AI college students, and identify factors that influence their decision-making. Modifiable risk factors are ideal to identify in that they can be targeted for health behavior education and intervention. Further, risk factors once identified can be tailored for designing effective interventions in high-risk communities.

Download Full-text

Interventions to improve human papillomavirus vaccination among Chinese female college students: study protocol for a randomized controlled trial

BMC Public Health ◽

10.1186/s12889-019-7903-x ◽

2019 ◽

Vol 19 (1) ◽

Author(s):

Mingyu Si ◽

Xiaoyou Su ◽

Yu Jiang ◽

Youlin Qiao ◽

Yuanli Liu

Keyword(s):

College Students ◽

Cervical Cancer ◽

Randomized Controlled Trial ◽

Hpv Vaccine ◽

Controlled Trial ◽

Hpv Vaccination ◽

Female College Students ◽

Behavioral Skill ◽

Global Average ◽

Randomized Controlled

Abstract Background While the HPV vaccines have been approved by the US FDA since 2006, in recent years an increasing number of women are living with cervical cancer globally. Among them, Chinese women have a higher cervical cancer incidence and mortality rate than the global average, with mortality rates being almost twice the global average. However, the current approach of HPV vaccination in China is not satisfactory given the high disease burden of cervical cancer. The current study is a randomized controlled trial designed to identify the barriers and facilitators of HPV vaccination among Chinese female students. This study will also test a health intervention measure via a popular form of new media in order to improve the HPV vaccine uptake under the framework of Information-Motivation-Behavioral skill Model (IMB). Methods This investigation is a multicenter, school-based, prospective, randomized, parallel group, double-blind, blank-controlled trial involving a 7-day education intervention with a further 6-month follow-up. We will enroll at least 3360 participants older than 18 years. The enrolled participants will be randomly divided into two groups (1:1 ratio). The intervention group will be offered a 7-day mobile health education, and participants in both groups will fill out 4 questionnaires at the baseline, 1 month, 3 months and 6 months after the intervention. The primary outcome is the difference in HPV vaccination or reservation for the HPV vaccine between the intervention and control groups. Secondary outcomes will include the comparison of (1) knowledge, attitudes, motivation, beliefs and behavioral skill about HPV and cervical cancer prevention, and (2) the willingness to uptake HPV vaccination. Discussion This study will examine the theory-based intervention in improving HPV vaccination among Chinese female college students. We will conduct the randomized controlled trial to provide scientific evidence on the potential effect of the IMB theory-based intervention. Findings from this study will contribute to a growing research field which assesses the effectiveness of mobile-based, school-targeted and theoretically guided interventions for promoting HPV vaccination in adolescents. Trial registration Chinese Clinical Trial Registry (ChiCTR), ChiCTR1900025476; Registered on 27 August 2019.

Download Full-text

Knowledge And Awareness About Human Papillomavirus, Cervical Cancer And HPV Vaccine Among College Students In Tripoli

10.37376/1570-000-038-005 ◽

2018 ◽

pp. 1

Author(s):

Rehab S. Jerbi ◽

Arij Mousa ◽

Mawadda F. Benhamza

Keyword(s):

College Students ◽

Cervical Cancer ◽

Human Papillomavirus ◽

Hpv Vaccine

Download Full-text

HPV Vaccine Knowledge and Perceived Risk of Cervical Cancer among Female College Students in Taiwan

Asian Pacific Journal of Cancer Prevention ◽

10.7314/apjcp.2013.14.12.7371 ◽

2013 ◽

Vol 14 (12) ◽

pp. 7371-7374 ◽

Cited By ~ 4

Author(s):

Hsiu-Ho Wang ◽

Shiao-Ying Wu

Keyword(s):

College Students ◽

Cervical Cancer ◽

Hpv Vaccine ◽

Perceived Risk ◽

Female College Students ◽

Female College

Download Full-text

HPV VACCINE AND CERVICAL CANCER

Journal of Medicine and Pharmacy ◽

10.34071/jmp.2011.3.15 ◽

2011 ◽

pp. 108-115

Author(s):

Vu Quoc Huy Nguyen

Keyword(s):

Cervical Cancer ◽

Relative Risk ◽

Hpv Vaccine ◽

Hpv Vaccination ◽

Preventive Strategy ◽

Protective Effects ◽

Papilloma Virus ◽

Vaccine Trials ◽

Close Relationship ◽

The Relationship

Persistent infection with high-risk Human Papilloma Virus (HPV) has been identified as the causal factor of cervical cancer, with relative risk up to 300-400 folds. This very close relationship leads to the preventive strategy of vaccination against HPV infections and HPV-related lesions. The article describes molecular and immunologic characteristics of HPV, currently available HPV vaccines and its protective effects; the relationship between HPV vaccination and cervical cancer screening, and an introduction to therapeutic HPV vaccine trials.

Download Full-text

From the Infection to the Immunotherapy in Cervical Cancer: Can We Stop the Natural Course of the Disease?

Vaccines ◽

10.3390/vaccines8040597 ◽

2020 ◽

Vol 8 (4) ◽

pp. 597

Author(s):

Daniela Luvero ◽

Salvatore Lopez ◽

Giorgio Bogani ◽

Francesco Raspagliesi ◽

Roberto Angioli

Keyword(s):

Cervical Cancer ◽

Radiation Therapy ◽

Risk Factor ◽

Hpv Vaccine ◽

Global Market ◽

Cancer Death ◽

Prevention Measures ◽

Primary And Secondary Prevention ◽

The World ◽

Prevention And Treatment

Cervical cancer (CC) is the second leading cause of cancer death in women aged 20–39 years. Persistent infection with oncogenic types of human papillomavirus (HPV) represents the most important risk factor for the development of cervical cancer. Three HPVs vaccines are currently on the global market: bivalent, quadrivalent, and nonavalent. The nonavalent vaccine provides protection against almost 90% of HPV-related CC. Despite availability of primary and secondary prevention measures, CC persists as one of the most common cancers among women around the world. Although CC is a largely preventable disease, management of persistent or recurrent CC no longer amenable to control with surgery or radiation therapy has not improved significantly with the progress of modern chemotherapy and disseminated carcinoma of the cervix remains a discouraging clinical entity with a 1-year survival rate between 10% and 15%. Over the last few years, there has been increasing interest in immunotherapy as a strategy to fight tumors. This article focuses on recent discoveries about the HPV vaccine and immunotherapies in the prevention and treatment of CC, highlighting the future view.

Download Full-text